Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News on Pharma

Mark Cuban Exposes How Wholesalers Force Pharmacies Into Near-Exclusive Deals, Detailing PBMs' 'Stranglehold' On Drug Pricing

Billionaire entrepreneur Mark Cuban, in a series of posts on the social media platform X early Monday morning, launched a scathing critique of the U.S. prescription drug industry, accusing large wholesalers and Pharmacy Benefit Managers (PBMs) of creating a “stranglehold” on pricing through opaque, anti-competitive practices.

Benzinga

Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks With Over 4% Dividend Yields

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout.

Benzinga

Syndax Gains Attention With Strong Drug Portfolio, Path To Leukemia Market Growth

Investors are increasingly looking to biotechnology companies for potential breakthroughs and profitable returns, as the sector shows resilience and growth amid broader market volatility. Within this landscape, Syndax Pharmaceuticals Inc. (NASDAQ:SNDX) is capturing attention with its promising drug portfolio and financial performance.

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

Why Is Sanofi Stock Falling Thursday?

On Thursday, Sanofi SA (NASDAQ:SNY) stock tumbled after late-stage trial results for amlitelimab, its potential successor to blockbuster eczema drug Dupixent, failed to match investor expectations, raising fresh doubts about the company’s ability to sustain its dermatology franchise once patent protections expire.

Benzinga

Sanofi Hit With Shock As Flagship Drug Successor Disappoints Investors

French drugmaker Sanofi SA (NASDAQ:SNY) stock fell sharply Thursday after late-stage trial results for amlitelimab, its potential successor to blockbuster eczema drug Dupixent, failed to match investor expectations, raising fresh doubts about the company’s ability to sustain its dermatology franchise once patent protections expire.

Benzinga

TG Therapeutics CEO Voices Strong Conviction In Briumvi With New $100 Million Buyback

TG Therapeutics Inc. (NASDAQ:TGTX) shares advanced Wednesday after the biopharmaceutical company announced the completion of a $100 million share repurchase program and unveiled plans for an additional $100 million buyback authorization.

Benzinga

4 Biotech Stocks That Are Showing Weakness: Momentum Scores Fading Over The Past Week

Several biotech stocks have seen their strength fade over the past week, with their Momentum scores in Benzinga’s Edge Stock Rankings witnessing a significant decline.

Benzinga

Read news from The Economist, FT, and more,
with one subscription

'Super lab': man denied bail after huge meth haul

A man has been accused of trying to flee overseas when police allegedly uncovered a drug "super lab" they claim could have produced $500 million worth of meth.

AAP

Analyst Favors Cigna, Alignment Healthcare, Cautious On Peers

Cigna Group’s (NYSE:CI) Evernorth Health Services announced on Tuesday a $3.5 billion investment in Shields Health Solutions, a specialty pharmacy management company.

Benzinga

Upstream's New Sinus Treatment Cuts Need For Surgery, Early Trial Finds

The medical landscape for chronic rhinosinusitis is rapidly advancing, with new treatments offering hope for improved quality of life for patients. As pharmaceutical companies race to develop effective therapies, recent clinical trials are shedding light on promising solutions.

Benzinga

Why Carisma Therapeutics Shares Are Trading Higher By 133%; Here Are 20 Stocks Moving Premarket

Shares of Carisma Therapeutics, Inc. (NASDAQ:CARM) rose sharply in pre-market trading after the company announced it will receive a $5 million investment from Ocugen as part of a merger with Ocugen’s subsidiary OrthoCelix.

Benzinga

Police Raid Suizo Argentina and Disability Agency in Explosive Graft Probe Tied to Milei's Sister

Argentine President Javier Milei's sister, Karina Milei, is accused of taking a 3% cut in a Suizo Argentina pharmaceutical deal with the National Disability Agency. Police raids, leaked recordings, and election-year tensions intensify the scandal.

Latin Times

Singapore is worried about a rise in drug-laced vaping. What is happening, and what is the drug etomidate?

Vaping has been banned since 2018, but now authorities are seeing a rise in young people using them to take an anaesthetic agent

The Guardian - AU

Who is Jim O’Neill? CDC chief set to bolster RFK Jr plan to remake vaccine policy

Ally of health secretary worked as speechwriter in George W Bush administration and has no training in medicine

The Guardian - US

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Teva Launches Generic GLP-1 Weight Loss Drug With FDA Nod For Saxenda

As the demand for affordable healthcare options grows, the pharmaceutical industry is increasingly focused on developing generic drugs to expand access and reduce costs. This trend is driving major players to seek FDA approvals for generic versions of popular medications, reshaping the competitive landscape and providing more choices for consumers.

Benzinga

Telix Gets Second FDA Rejection For Kidney Cancer Drug

On Thursday, Telix Pharmaceuticals Limited (NASDAQ:TLX) received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) for the Biologics License Application (BLA) for TLX250-CDx (Zircaix, 89Zr-DFO girentuximab), an investigational PET2 agent for the diagnosis and characterization of renal masses as clear cell renal cell carcinoma (ccRCC).

Benzinga

What's Going On With Tilray Stock Today?

Tilray Brands, Inc. (NASDAQ:TLRY) shares gained ground on Thursday after the marijuana company’s medical division expanded its portfolio in Germany with three newly certified cannabis strains.

Benzinga

FDA Rejects Outlook Therapeutics Eye Drug For Second Time

Outlook Therapeutics, Inc. (NASDAQ:OTLK) stock plunged on Thursday after the U.S. Food and Drug Administration (FDA) update.

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Top 5 Biotech Stocks With Strong Momentum

Among biotechnology stocks, several names have hovered around the top momentum percentile this week, signaling robust bullish activity and potential for short-term gains.

The Guardian - UK

Mounjaro maker pauses shipments of weight loss drug to UK

US firm Eli Lilly reportedly tells British wholesalers to stop taking orders as demand soars before September price rise

Evening Standard

Mounjaro weight loss jab sales are halted in the UK as drugmaker looks to beat price rise

Eli Lilly, the manufacturer of Mounjaro, has temporarily suspended deliveries of the drug to UK pharmacies in response to ‘unprecedented demand’

Benzinga

Why MongoDB Shares Are Trading Higher By 31%; Here Are 20 Stocks Moving Premarket

Shares of MongoDB, Inc. (NASDAQ:MDB) rose sharply in pre-market trading after the company posted better-than-expected second-quarter results after the closing bell on Tuesday.

The Texas Tribune

Texas Legislature approves bill making ivermectin an over-the-counter drug

Some people use the drug to treat COVID, even though it’s not approved by the FDA for such use. The bill now awaits the governor’s signature.

The Guardian - UK

Tough talk from Streeting – but he still needs a deal with big pharma

Health secretary calls industry ‘shortsighted’ but there is danger in giving UK better terms than much of rich Europe

Benzinga

NovaBay Pharmaceuticals Stock Soars 48% After Hours, Following Special Dividend Declaration

NovaBay Pharmaceuticals Inc. (NYSEAMERICAN: NBY) shares jumped 48.31% in after-hours trading on Tuesday, reaching $1.32 after closing the regular session at $0.89. The biotech company’s board declared a one-time special cash dividend of $0.80 per share.

1 … 10 11 12 13

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.